Epigenomics

Epigenomics is located in Seattle, United States on 901 5th Ave. Epigenomics is rated 3 out of 5 in the category biotechnology companylaboratory in United States. Home - epigenomics Company About us Management Supervisory Board Careers Products Epi proColon® HCCBloodTest Epi proLung® Epi BiSKit Research & Development Mission DNA Methylation Pipeline Septin9 biomarker News & Investors Share information Shareholders Analyst coverage ADR Program Share Price News Press Releases Voting Rights Downloads Financial Reports Corporate Governance Supervisory Board Directors’ Dealings General Shareholders’ Meeting Financial Calendar FAQ Capital increase Contact Contact Pharma Webdesign Berlin Menu en de Company About us Management Supervisory Board Careers Products Epi proColon® HCCBloodTest Epi proLung® Epi BiSKit Research & Development Mission DNA Methylation Pipeline Septin9 biomarker News & Investors Share information Shareholders Analyst coverage ADR Program Share Price News Press Releases Voting Rights Downloads Financial Reports Corporate Governance Supervisory Board Directors’ Dealings General Shareholders’ Meeting Financial Calendar FAQ Capital increase Contact Contact Detecting Cancer in Blood Our minimally-invasive blood-based tests detect cancer in a simple blood draw. Learn more Want to stay updated? Subscribe to our newsletters. For free. Have questions? Our live support would be happy to help you. Saving lives through blood-based cancer detection Our high-performing, minimally-invasive tests have the potential to radically improve cancer detection. By leveraging our expertise in epigenetics we are uniquely positioned to drive patient access to cancer testing through liquid biopsy. Epi proColon® Epi proColon® is an innovative screening test for the detection of colorectal cancer – with a simple blood draw. Epi proColon® is available in the U.S., South America, and Europe. LEARN MORE HCCBloodTest The HCCBloodTest detects methylated SEPT9 DNA, that serves as an aid in the detection of hepatocellular carcinoma (HCC) in patients with cirrhosis. The HCCBloodTest CE is available in Europe and is undergoing clinical evaluation for the registration in the U.S. LEARN MORE Regular colorectal cancer screening can save lives. Take responsibility for yourself and those you love. Colorectal cancer is the third most common cancer in the world. If detected early, colorectal cancer is highly curable. But still, millions of eligible patients do not undergo colorectal cancer screening. Talk to your doctor about Epi proColon®, our convenient blood-test for colorectal cancer screening. Colorectal cancer is one of the most curable cancers – if detected early. Due to low compliance to screening guidelines, nearly 60% of colorectal cancer diagnoses being made in the disease’s late stages, where survival prognosis is low. Only 40% of colorectal cancer cases are detected in early stages. Early stage Late stage Source: American Cancer Society, Cancer Facts & Figures 2015 Epigenomics AG Geneststraße 5 10829 Berlin Germany Phone: +49 30 24345-0 Fax: +49 30 24345-555 [email protected] Epigenomics Inc. 11055 Flintkote Ave, Suite A San Diego, California 92121, USA Toll Free: +1 844 537 4669 (844-5-EPI NOW) Local: +1 858 429 6199 Fax: +1 858 496 7253 [email protected] Home Contact Imprint Data Protection Statement Disclaimer